BIO101 in Sarcopenia

The most advanced clinical program worldwide

The most advanced clinical program worldwide

Medical Need:

Sarcopenia is a disease characterized by progressive and generalized loss of skeletal muscle mass and strength and declining physical performance, with an increased risk of adverse events such as disability, reduced quality of life and mortality.

  • 1 in 4 people aged 60 and over worldwide is affected
  • 178% increased risk of falls
  • 3-fold increased risk of mortality
  • 6 years of life expectancy lost
To date, no pharmacological therapy has been approved.

Phase II clinical trial results (SARA-INT):

In the SARA-INT Phase II trial, BIO101 demonstrated significant improvement in mobility outcomes, establishing its position as the most advanced candidate in sarcopenia.

  • 11% improvement in gait speed (400-meter walk test)
  • Clinically meaningful improvement in physical function